Skip to main content

ERRATUM article

Front. Oncol., 06 December 2022
Sec. Neuro-Oncology and Neurosurgical Oncology
Volume 12 - 2022 | https://doi.org/10.3389/fonc.2022.1085757

Erratum: Hepcidin is upregulated and is a potential therapeutic target associated with immunity in glioma

This article is an erratum on:

  1. Hepcidin is upregulated and is a potential therapeutic target associated with immunity in glioma

    1. Read original article
Frontiers Production Office* Frontiers Production Office*
  • Frontiers Media SA, Lausanne, Switzerland

An Erratum on
Hepcidin is upregulated and is a potential therapeutic target associated with immunity in glioma

by Dong T, Zhang B, Zhang R, Wang C, Liu X, Wang F, Hao N, Tan K, and Chang Y-Z (2022) 12:963096. doi: 10.3389/fonc.2022.963096

Due to a production error, there was an error in affiliation 1. Instead of “Key Laboratory of Molecular and Cellular Biology of Ministry of Education, Key Laboratory of Animal Physiology, Biochemistry and Molecular Biology of Hebei Province, College of Life Sciences, Shijiazhuang, China”, it should be “Key Laboratory of Molecular and Cellular Biology of Ministry of Education, Key Laboratory of Animal Physiology, Biochemistry and Molecular Biology of Hebei Province, College of Life Sciences, Hebei Normal University, Shijiazhuang, China”.

The publisher apologizes for this mistake. The original version of this article has been updated.

Keywords: hepcidin, glioma, prognostic biomarker, immune cell infiltration, iron

Citation: Frontiers Production Office (2022) Erratum: Hepcidin is upregulated and is a potential therapeutic target associated with immunity in glioma. Front. Oncol. 12:1085757. doi: 10.3389/fonc.2022.1085757

Received: 31 October 2022; Accepted: 25 November 2022;
Published: 06 December 2022.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2022 Frontiers Production Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Frontiers Production Office, cHJvZHVjdGlvbi5vZmZpY2VAZnJvbnRpZXJzaW4ub3Jn

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.